Key facts
- Provet Pharma’s last known valuation is $260K (Mar 2015).
- It has raised $130K; the latest was Later Stage VC in Mar 2026.
- Notable investors include Growel Formulations, N+1 Capital (India).
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Provet Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Provet Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Provet Pharma
Manufacturer of veterinary pharmaceuticals and animal health products intended to support livestock and companion animal care. The company offers veterinary medicines and nutritional supplements, enabling veterinarians, livestock owners, and pet caregivers in India to provide animal healthcare, prevent diseases, and improve productivity.
- Sector
- Healthcare
- HQ
- Chennai, India
- Founded
- 2009
- Employees
- 64
- Website
- provet.in/
- Ownership
- Privately Held (backing)
Provet Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Provet Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Provet Pharma in its N-PORT filings yet. We sweep new filings monthly.